Articles dans des revues avec comité de lecture (396)
  1. 97. Awada, A., Cortes, J., Martin, M., Aftimos, P., Oliveira, M., López-Tarruella, S., Espie, M., Lardelli, P., Extremera, S., Fernández-García, E. E., & Delaloge, S. (2016). Phase 2 Study of Trabectedin in Patients With Hormone Receptor–Positive, HER-2–Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. Clinical breast cancer, 16(5), 364-371. doi:10.1016/j.clbc.2016.05.005
  2. 98. Morgan, G., Aftimos, P., & Awada, A. (2016). Current-day precision oncology: From cancer prevention, screening, drug development, and treatment - Have we fallen short of the promise? Current opinion in oncology, 28(5), 441-446. doi:10.1097/CCO.0000000000000318
  3. 99. Kourie Hampig, R., Chaix, M., Gombos, A., Aftimos, P., & Awada, A. (2016). Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opinion on Drug Metabolism & Toxicology, 12(8), 947-957. doi:10.1080/17425255.2016.1198317
  4. 100. Kourie Hampig, R., Awada, G., & Awada, A. (2016). Rare side-effects of checkpoint inhibitors. Current opinion in oncology, 28(4), 295-305. doi:10.1097/CCO.0000000000000294
  5. 101. Sideris, S., Aoun, F., Martinez, C. C., Latifyan, S., Awada, A., Costante, G., & Gil, T. (2016). Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. Journal of endocrinological investigation, 39(7), 729-738. doi:10.1007/s40618-016-0430-z
  6. 102. Ignatiadis, M., Zardavas, D., Lemort, M., Wilke, C., Vanderbeeken, M., D'Hondt, V., de Azambuja, E., Gombos, A., Lebrun, F., Dal Lago, L., Bustin, F., Maetens, M. M., Ameye, L., Veys, I., Michiels, S., Paesmans, M., Larsimont, D., Sotiriou, C., Nogaret, J.-M., Piccart-Gebhart, M., & Awada, A. (2016). Feasibility study of EndoTAG-1, a tumor endothelial targeting agent, in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer. PloS one, 11(7), e0154009. doi:10.1371/journal.pone.0154009
  7. 103. Aftimos, P., Polastro, L., Ameye, L., Jungels, C., Vakili, J., Paesmans, M., Van Den Eerenbeemt, J., Buttice, A., Gombos, A., de Valeriola, D., Gil, T., Piccart-Gebhart, M., & Awada, A. (2016). Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. European journal of cancer, 60, 117-124. doi:10.1016/j.ejca.2016.03.010
  8. 104. Kotecki, N., Penel, N., Awada, A., Bonneterre, J., Hebbar, M., Adenis, A., Cortot, A. B., Cousin, S., Clisant, S., & Duhamel, A. (2016). Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue. Pharmaceutical Medicine, 30(3), 143-147. doi:10.1007/s40290-016-0138-6
  9. 105. Twelves, C., Awada, A., Cortes, J., Yelle, L., Velikova, G., Olivo, M. M., Song, J., Dutcus, C. C., & Kaufman, P. P. (2016). Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer, 10, 77-84. doi:10.4137/BCBCR.S39615
  10. 106. Kourie Hampig, R., Awada, G., & Awada, A. (2016). Learning from the "tsunami" of immune checkpoint inhibitors in 2015. Critical reviews in oncology/hematology, 101, 213-220. doi:10.1016/j.critrevonc.2016.03.017
  11. 107. Awada, A., Campone, M., Varga, A., Aftimos, P., Frenel, J. S., Bahleda, R., Gombos, A., Bourbouloux, E., & Soria, J.-C. (2016). An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Anti-cancer drugs, 27(4), 342-348. doi:10.1097/CAD.0000000000000336
  12. 108. Twelves, C., Jove, M., Gombos, A., & Awada, A. (2016). Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. Critical reviews in oncology/hematology, 100, 74-87. doi:10.1016/j.critrevonc.2016.01.021
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>